NASDAQ: PRFXPainreform Ltd Stock
$1.94-0.18 (-8.49%)
Updated May 8, 2025
PRFX Price
$1.94
Fair Value Price
N/A
Market Cap
$2.85M
52 Week Low
$1.68
52 Week High
$20.88
P/E
-0.06x
P/B
1.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.48
Operating Cash Flow
-$13M
Beta
0.92
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PRFX Overview
PainReform Ltd. develops reformulations of established pain therapeutics. Its PRF-110 product is a viscous clear oil-based solution instilled directly into surgical wounds to provide localized and extended post-operative analgesia. PRF-110 is in clinical trials related to bunionectomy surgeries and hernia repairs. PainReform was incorporated in 2007 and is headquartered in Tel Aviv, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRFX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
PRFX
Ranked#60 of 60
Ranked#60 of 60
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.25 | A | |
| $4.50 | A | |
| $7.46 | A |
Be the first to know about important PRFX news, forecast changes, insider trades & much more!
PRFX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRFX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRFX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRFX is good value based on its book value relative to its share price (1.56x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.16x)
P/B vs Industry Valuation
PRFX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRFX due diligence checks available for Premium users.
Valuation
PRFX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
15.04x
Market
24.22x
PRFX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.56x
Industry
2.16x
PRFX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRFX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PRFX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.5M
Liabilities
$2.7M
Debt to equity
1.48
PRFX's short-term assets ($4.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRFX's short-term assets ($4.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRFX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRFX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PRFX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRFX vs Pharmaceutical Stocks
Painreform Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.